Sign Up to like & get recommendations! 1
Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202201291
Abstract: The left ventricular assist device (LVAD) is often used in the treatment of heart failure. However, 4% to 9% implanted LVAD will have thrombosis problem in one year, which is fatal to the patient's life.… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.28375
Abstract: Transcatheter aortic valve implantation (TAVI) has become a well‐established therapeutic option for patients with severe aortic stenosis (AS) at high to intermediate surgical risk. Although TAVI is associated with low mortality of 1.2–6.5%, cardiogenic shock… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.28560
Abstract: Over the last decade, there has been a significant increase in the use of percutaneous left ventricular assist devices(p‐LVADs). p‐LVADs are being increasingly used during complex coronary interventions and for acute cardiogenic shock. These large… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30230
Abstract: To assess the outcomes of a single‐center experience with percutaneous left ventricular assist device (LVAD) decommissioning. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30241
Abstract: Left ventricular assist devices (LVAD) outflow graft obstruction is an uncommon complication but carries significant morbidity and mortality. Here we provide a case series of patients with LVAD intrinsic outflow graft obstruction who are deemed… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13267
Abstract: Left ventricular assist device therapy has become the cornerstone in the treatment of end‐stage heart failure and is increasingly used as destination therapy next to bridge to transplant or recovery. HeartMate 3 (HM3) and HeartWare… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13537
Abstract: Recipients of left ventricular assist devices (LVAD) are exposed to increased risk of adverse clinical events. One of the potential contributing factors is non‐pulsatile flow generated by LVAD. We evaluated the association of flow patterns… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13769
Abstract: We report the first case of an investigational maglev extracorporeal ventricular assist device (extra‐VAD) use in China for a patient with cardiogenic shock post‐coronary artery bypass surgery. There were no extra‐VAD devices available for clinical… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13951
Abstract: The removal of left ventricular assist device (LVAD) after myocardial recovery can provide survival benefits with freedom from LVAD‐associated complications. However, in the absence of standardization, the weaning evaluation and surgical strategy differ widely among… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14203
Abstract: Exercise games (exergames) have been recently proposed as a mode of facilitating physical activity in patients with chronic diseases. Although patients supported with left ventricular assist devices (LVADs) benefit from physical activity, specific LVAD‐related issues… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "ESC heart failure"
DOI: 10.1002/ehf2.14366
Abstract: AIMS Phosphodiesterase-5 inhibitors (PDE5I) are frequently implemented after left ventricular assist device (LVAD) implantation to improve haemodynamics in patients with early postoperative right ventricular (RV) failure. It is unknown if long-term PED5I therapy beyond the… read more here.